

In the claims:

1-32. **(cancelled)**

33. **(new)** An antibody or fragment thereof which binds to a B7RP1 polypeptide of amino acid residues 1-322 or 47-322 as set forth in Figure 2A (SEQ ID NO:7).

34. **(new)** An antibody or fragment thereof which binds to a B7RP1 polypeptide of amino acid residues 1-288 or amino acid residues 19-288, 20-288, 21-288, 22-288, 24-288 or 28-288 as set forth in Figure 3A (SEQ ID NO:12).

35. **(new)** An antibody or fragment thereof which binds to a B7RP1 polypeptide of amino acid residues 1-302 or amino acid residues 19-302, 20-302, 21-302, 22-302, 24-302 or 28-302 as set forth in Figure 12A (SEQ ID NO:17).

36. **(new)** An antibody or fragment thereof which binds to a mature form of a B7RP1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17) but does not bind to the mature form of a B7RP1 polypeptide of Figure 2A (SEQ ID NO:7).

37. **(new)** An antibody or fragment thereof which binds to a mature form of a B7RP1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17) and to a mature form of a B7RP1 polypeptide of Figure 2A (SEQ ID NO:7).

38. **(new)** The antibody or fragment of Claims 34, 35, 36 or 37 which binds to a membrane-associated form of a B7RP1 polypeptide of Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

39. **(new)** The antibody or fragment of Claims 34, 35, 36 or 37 which binds to a soluble form of a B7RP1 polypeptide of Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

40. **(new)** The antibody or fragment of Claims 34, 35, 36 or 37 which binds to an extracellular domain, or fragment thereof, of a B7RP1 polypeptide of Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

41. **(new)** The antibody or fragment of Claims 34, 35, 36 or 37 which partially or completely blocks the binding of B7RP1 to CRP1.

42. **(new)** The antibody or fragment of Claims 34, 35, 36 or 37 which is an agonist antibody.

43. **(new)** The antibody or fragment of Claims 34, 35, 36 or 37 which is an antagonist antibody.

44. **(new)** The antibody or fragment of Claims 34, 35, 36 or 37 which partially or completely inhibits immune costimulatory activity.

45. **(new)** An antibody or fragment thereof which binds to a polypeptide encoded by the nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 6).

46. **(new)** An antibody or fragment thereof which binds to a polypeptide encoded by the nucleotide sequence as set forth or Figure 3A (SEQ ID NO: 11) or Figure 12A (SEQ ID NO: 16).

47. **(new)** The antibody or fragment of Claim 45 which binds to a soluble form of B7RP1, wherein B7RP1 is encoded by the nucleic acid of Figure 3A (SEQ ID NO:11) or Figure 12A (SEQ ID NO:16).

48. **(new)** The antibody of Claims 34, 35, 36 or 37 which is a monoclonal antibody.

49. **(new)** The antibody of Claims 34, 35, 36 or 37 which is a chimeric antibody.

50. **(new)** The antibody of Claims 34, 35, 36 or 37 which is a single chain antibody.

51. **(new)** The antibody of Claims 34, 35, 36 or 37 which is a bispecific antibody.

52. **(new)** The antibody of Claims 34, 35, 36 or 37 which is a CDR-grafted or humanized antibody.

53. **(new)** The antibody of Claims 34, 35, 36 or 37 which is a human antibody.

54. **(new)** A pharmaceutical composition comprising the antibody of Claims 34, 35, 36 or 37 and a carrier, diluent, and/or excipient.